Exhibit 99.1

 

 

Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results

Second-Quarter 2023 Results:

— Net Sales of $945.0 Million, Representing Year-Over-Year Growth of 11%

Excluding Inflammation Medicines —

— GAAP Net Income of $127.1 Million; Adjusted EBITDA of $320.4 Million —

— TEPEZZA^® (teprotumumab-trbw) Net Sales of $445.5 Million —

— KRYSTEXXA^® (pegloticase injection) Net Sales of $244.3 Million —

— UPLIZNA^® (inebilizumab-cdon) Net Sales of $68.1 Million —

— Cash Position of $2.5 Billion as of June 30, 2023 —

Second-Quarter and Recent Company Highlights:

— Announced Positive Topline Data from TEPEZZA Phase 4 Clinical Trial in Patients with

Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED) —

— Obtained U.S. FDA Approval for Updated TEPEZZA Indication to Specify Treatment of

TED Patients Regardless of Disease Activity or Duration —

— Announced Positive Topline Data from TEPEZZA Phase 3 Clinical Trial (OPTIC-J) in Japanese Patients —

— Received Approval for TEPEZZA in Brazil for the Treatment of TED; First Country Outside the

U.S. to Approve TEPEZZA —

— Announced Initiation of TEPEZZA Phase 3 Clinical Trial in Chronic/Low CAS TED in Japan and

Daxdilimab Phase 2 Clinical Trial in Lupus Nephritis —

— Presented New Data from Dazodalibep Phase 2 Clinical Trial in Sjögren’s Syndrome and

KRYSTEXXA MIRROR Randomized Controlled Trial at EULAR European Congress of Rheumatology —

— Continue to Expect Amgen Transaction to Close by Mid-December, Assuming the

Federal Trade Commission’s Request for a Preliminary Injunction Is Denied —

— Named One of Fortune’s 100 Best Companies to Work For^® and Ranked as Top

Biotechnology/Pharmaceutical Company, Both for Third Consecutive Year —

— Ranked First in Overall Corporate Reputation by U.S. Patient Advocacy Groups —

DUBLIN – Aug. 8, 2023 – Horizon Therapeutics plc (Nasdaq: HZNP) today announced second-quarter 2023 financial results.

“We delivered strong growth in the second quarter, with double-digit year-over-year growth in our core business and mid-teens growth sequentially,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “This performance was driven by exceptional 46% year-over-year KRYSTEXXA sales growth as a result of strong commercial execution and the success of our immunomodulation strategy, in addition to positive and consistent trends we are generating for TEPEZZA, which reflects the success of our expansion efforts to further penetrate the TED market and reach new prescribers. We delivered impressive 76% year-over-year UPLIZNA sales growth and see a long runway ahead as we progress our two Phase 3 programs in IgG4-RD and MG. We also announced several important clinical milestones for TEPEZZA, including strong data in low CAS and long-duration TED and data from our Phase 3 clinical trial in Japan, both of which we expect to contribute to the future growth of this medicine.”

 

Financial Highlights

 

(in millions except for per share amounts and percentages)		Q2 23				Q2 22				% Change				YTD 23				YTD 22				% Change
Net sales		$	945.0			$	876.4				8			$	1,777.0			$	1,761.7				1
Net income			127.1				61.0				108				181.8				265.2				(31	)
Non-GAAP net income			280.1				253.8				10				474.4				569.6				(17	)
Adjusted EBITDA			320.4				306.6				4				553.3				677.8				(18	)
Earnings per share - diluted			0.54				0.26				108				0.78				1.12				(30	)
Non-GAAP earnings per share - diluted			1.20				1.07				12				2.03				2.41				(16	)

Second-Quarter and Year-to-Date 2023 Net Sales Results

 

(in millions except for percentages)		Q2 23				Q2 22				% Change				YTD 23				YTD 22				% Change
TEPEZZA®		$	445.5			$	479.8				(7	)		$	850.8			$	981.3				(13	)
KRYSTEXXA®			244.3				167.8				46				431.3				308.5				40
RAVICTI®			88.4				75.7				17				178.7				154.1				16
UPLIZNA®(1)			68.1				38.6				76				121.9				69.1				76
PROCYSBI®			53.1				47.7				11				103.6				97.3				7
ACTIMMUNE®			29.0				30.0				(3	)			58.2				61.3				(5	)
PENNSAID 2%®(2)			7.0				23.6				(70	)			16.1				59.0				(72	)
RAYOS®			8.0				11.1				(28	)			13.0				24.6				(47	)
BUPHENYL®			1.3				1.4				(10	)			2.6				3.5				(25	)
QUINSAIRTM			0.3				0.3				3				0.6				0.6				1
DUEXIS®			—				0.1				(100	)			0.1				1.2				(91	)
VIMOVO®			—				0.3				(100	)			0.1				1.2				(91	)
Total Net Sales(3)		$	945.0			$	876.4				8			$	1,777.0			$	1,761.7				1

 

(1)	Second-quarter and year-to-date 2023 UPLIZNA net sales included $15.4 million and $22.0 million, respectively, in international net sales. Second-quarter and year-to-date 2022 UPLIZNA net sales included $8.6 million and $13.8 million, respectively, in international net sales.

(2)	On May 6, 2022, Apotex Inc. initiated an at-risk launch of generic PENNSAID 2% in the United States.

(3)	Excluding the Company’s inflammation business unit (RAYOS, PENNSAID 2%, DUEXIS and VIMOVO), which was wound down at the end of 2022 due to generic competition, second-quarter year-over-year net sales growth was 11%.

Key Growth Drivers

TEPEZZA: TEPEZZA net sales in the second quarter were $446 million, representing a 10% sequential increase compared to the first quarter of 2023 and a 7% year-over-year decline compared to the second quarter of 2022. The TEPEZZA field-force expansion initiated late in 2022 continues to drive consistent and positive momentum in the business, including increases in new prescribers, patient enrollment forms and patient starts. Through the first half of 2023, as a result of the field-force expansion, the Company expanded its reach to new physician targets, which led to a 50% year-over-year increase in the number of ophthalmologists and endocrinologists prescribing TEPEZZA. In line with the Company’s expansion strategy, prescriber growth has largely come from ophthalmologists, with continued strong referral volume from endocrinologists.

 

2

 

In April 2023, the Company announced positive topline results from its TEPEZZA Phase 4 clinical trial in patients with low CAS and long-duration TED and received FDA approval for an update to the indication for TEPEZZA that supports its potential benefit in TED, regardless of disease activity or duration. The Company is executing on its payer strategy to educate key stakeholders and ease the access burden so all eligible patients can benefit from TEPEZZA. As a result of this process, large national and regional payers are beginning the process of updating their access requirements. To date, the Company has obtained favorable policy changes for greater than 20% of U.S. covered lives, which are expected to take effect in the second half of 2023. The Company expects these strategies and initiatives to further develop the TED market and impact net sales in 2024.

In addition, the Company made significant advancements in its global expansion strategy by announcing the positive topline results from its TEPEZZA Phase 3 clinical trial in Japanese patients, as well as the approval of TEPEZZA in Brazil for patients with TED. There are no medicines approved for the treatment of TED in Brazil or Japan, representing a significant unmet need in both markets. These accomplishments, which are expected to impact net sales beginning in 2025, are important milestones in the Company’s global expansion strategy to bring TEPEZZA to more patients worldwide.

KRYSTEXXA: KRYSTEXXA net sales in the second quarter were a record $244 million, representing a 31% sequential increase compared to the first quarter of 2023 and a 46% year-over-year increase compared to the second quarter of 2022. KRYSTEXXA net sales are now annualizing at a nearly one-billion-dollar run rate. The second-quarter results were driven by execution across all phases of the patient journey – demand generation, stakeholder education and adherence to treatment. The Company continued to see significant uptake from both its rheumatology and nephrology market segments in the quarter, with KRYSTEXXA with immunomodulation usage now at more than 70% of new patient starts. The Company’s efforts to educate physicians and key stakeholders continues to lead to strong patient growth from both new and existing prescribers across both market segments.

UPLIZNA: UPLIZNA net sales in the second quarter were a record $68 million, representing a 27% sequential increase compared to the first quarter of 2023 and a 76% year-over-year increase compared to the second quarter of 2022. Net sales in the U.S. were $53 million, an increase of 76% year-over-year, driven by strong commercial execution. The second-quarter results were driven by robust demand generation and new patient starts, increased depth among the Company’s existing prescribers and strong adherence to maintenance treatment. The Company continues to drive uptake among both patients naïve to biologics as well as patients switching from competitive biologic therapies, establishing UPLIZNA as the fastest-growing biologic in neuromyelitis optica spectrum disorder (NMOSD) year-to-date by market share. The Company expects to advance its global expansion strategy, with multiple planned international launches in 2023. The Company also continues to make progress on its two Phase 3 programs in IgG4-related disease (IgG4-RD) and myasthenia gravis (MG).

Conference Call

In light of the announced agreement to be acquired by Amgen Inc. and applicable securities laws, the Company will not be hosting a conference call to discuss its financial results. This earnings press release, investor deck and the related Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 are publicly available in the Investor Relations section of the Company’s website at https://ir.horizontherapeutics.com.

 

3

 

About Horizon

Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

Note Regarding Use of Non-GAAP Financial Measures

Horizon provides certain non-GAAP financial measures, including EBITDA, or earnings before interest, taxes, depreciation and amortization, adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross profit and gross profit ratio, non-GAAP operating expenses, non-GAAP operating income, non-GAAP tax benefit (expense) and tax rate, non-GAAP operating cash flow and certain other non-GAAP income statement line items, each of which include adjustments to GAAP figures. These non-GAAP measures are intended to provide additional information on Horizon’s performance, operations, expenses, profitability and cash flows. Adjustments to Horizon’s GAAP figures exclude, as applicable, acquisition and/or divestiture-related costs, costs associated with our pending transaction with Amgen Inc., including responding to a second request review of the transaction by the United States Federal Trade Commission (the “FTC”) and subsequent lawsuit seeking to enjoin the transaction, manufacturing facility start-up costs, restructuring and realignment costs and gain on sale of asset, as well as non-cash items such as share-based compensation, inventory step-up expense, depreciation and amortization, non-cash interest expense, goodwill and long-lived assets impairment charges, gain (loss) on equity security investments and other non-cash adjustments. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Horizon maintains an established non-GAAP cost policy that guides the determination of what costs will be excluded in non-GAAP measures. Horizon believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Horizon’s financial and operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of the Company’s historical and expected financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators Horizon’s management uses for planning and forecasting purposes and measuring the Company’s performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies.

 

4

 

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the pending transaction with Amgen Inc., development, manufacturing and commercialization plans; expected timing of clinical trials and commercial launches; expected future milestones, pipeline expansions and regulatory approvals; potential market opportunities for, and benefits of, Horizon’s medicines and medicine candidates; expected impact of commercial strategies, clinical trial results and product label updates; and business and other statements that are not historical facts. These forward-looking statements are based on Horizon’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, whether the pending transaction with Amgen Inc. will be completed in a timely manner or at all, including whether the district court grants or denies the FTC’s request for a preliminary injunction; the parties’ ability to satisfy (or willingness to waive) the conditions to the consummation of the pending transaction with Amgen Inc., including with respect to the absence of orders preventing the consummation of the transaction; the effect of the pending transaction with Amgen Inc. on Horizon’s business relationships, operating results and business generally; risks that Horizon’s actual future financial and operating results may differ from its expectations or goals; Horizon’s ability to grow net sales from existing medicines; impacts of the on-going war between Russia and Ukraine; changes in inflation, interest rates and general economic conditions; the availability of coverage and adequate reimbursement and pricing from government and third-party payers; Horizon’s ability to successfully implement its business strategies, including the risks that its medicine growth and global expansion initiatives and strategies may not be successful and that new challenges to growth may arise in the future; risks inherent in developing novel medicine candidates and existing medicines for new indications; whether additional clinical trial results or data analyses will be consistent with preliminary results, results from other trials or Horizon’s expectations; risks associated with regulatory approvals; risks in the ability to recruit, train and retain qualified personnel; competition, including generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight, including any changes in the legal and regulatory environment in which Horizon operates and those risks detailed from time-to-time under the caption “Risk Factors” and elsewhere in Horizon’s filings and reports with the SEC. Horizon undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information.

 

Contacts:
Investors:		U.S. Media:
Tina Ventura		Geoff Curtis
Senior Vice President,		Executive Vice President,
Chief Investor Relations Officer		Corporate Affairs & Chief Communications Officer
[email protected]		[email protected]
Erin Linnihan
Executive Director,		Ireland Media:
Investor Relations		Eimear Rigby
[email protected]		[email protected]

 

5

 

Horizon Therapeutics plc

Condensed Consolidated Statements of Operations (Unaudited)

(in thousands, except share and per share data)

 

		Three Months Ended June 30,								Six Months Ended June 30,
		2023				2022				2023				2022
Net sales		$	944,959			$	876,411			$	1,777,018			$	1,761,656
Cost of goods sold			219,958				230,216				428,521				445,278
Gross profit			725,001				646,195				1,348,497				1,316,378
OPERATING EXPENSES:
Research and development (1)			150,035				103,246				284,183				206,378
Selling, general and administrative			434,125				398,221				887,479				770,955
Impairment of goodwill			—				56,171				—				56,171
Gain on sale of asset			(2,000	)			—				(2,000	)			—
Total operating expenses			582,160				557,638				1,169,662				1,033,504
Operating income			142,841				88,557				178,835				282,874
OTHER EXPENSE, NET:
Interest expense, net			(12,098	)			(21,409	)			(27,638	)			(42,665	)
Foreign exchange gain			326				28				417				448
Other income (expense), net			4,183				(2,389	)			2,840				(3,131	)
Total other expense, net			(7,589	)			(23,770	)			(24,381	)			(45,348	)
Income before expense (benefit) for income taxes			135,252				64,787				154,454				237,526
Expense (benefit) for income taxes			8,181				3,813				(27,301	)			(27,709	)
Net income		$	127,071			$	60,974			$	181,755			$	265,235
Net income per ordinary share - basic		$	0.56			$	0.27			$	0.80			$	1.16
Weighted average ordinary shares outstanding - basic			228,743,143				230,020,004				228,571,356				229,559,715
Net income per ordinary share - diluted		$	0.54			$	0.26			$	0.78			$	1.12
Weighted average ordinary shares outstanding - diluted			233,935,591				236,166,384				233,938,149				236,077,147

 

(1)

Beginning with the third quarter of 2022, the Company is separately presenting upfront, milestone, and similar payments pursuant to collaborations, licenses of third-party technologies, and asset acquisitions as “Acquired in-process research and development and milestones” expenses in the condensed consolidated statement of comprehensive income. Amounts recorded in this line item would have historically been recorded to research and development (“R&D”) expenses. The Company believes the new classification assists users of the financial statements in better understanding the payments incurred to acquired in-process research and development, or IPR&D. Prior period consolidated statements of comprehensive income have been reclassified to conform with the new classification. There were no acquired IPR&D and milestones expenses during the three and six months ended June 30, 2023 and 2022.

 

6

 

Horizon Therapeutics plc

Condensed Consolidated Balance Sheets (Unaudited)

(in thousands, except share data)

 

		As of
		June 30, 2023				December 31, 2022
ASSETS
CURRENT ASSETS:
Cash and cash equivalents		$	2,464,623			$	2,352,833
Restricted cash			4,791				4,755
Accounts receivable, net			717,417				676,347
Inventories, net			170,325				169,559
Prepaid expenses and other current assets			564,808				449,349
Total current assets			3,921,964				3,652,843
Property, plant and equipment, net			362,326				340,509
Developed technology and other intangible assets, net			2,486,565				2,664,777
In-process research and development			810,000				810,000
Goodwill			1,010,538				1,010,538
Deferred tax assets, net			444,306				431,814
Other long-term assets			263,042				204,135
Total assets		$	9,298,741			$	9,114,616
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable		$	85,543			$	155,800
Accrued expenses and other current liabilities			496,669				457,557
Accrued trade discounts and rebates			319,469				319,780
Long-term debt—current portion			16,000				16,000
Total current liabilities			917,681				949,137
LONG-TERM LIABILITIES:
Long-term debt, net			2,541,458				2,546,837
Deferred tax liabilities, net			264,815				342,017
Other long-term liabilities			263,828				204,451
Total long-term liabilities			3,070,101				3,093,305
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:
Ordinary shares, $0.0001 nominal value; 600,000,000 shares authorized at June 30, 2023 and December 31, 2022; 229,323,393 and 227,625,913 shares issued at June 30, 2023 and December 31, 2022, respectively; and 228,939,027 and 227,241,547 shares outstanding at June 30, 2023 and December 31, 2022, respectively			23				23
Treasury stock, 384,366 ordinary shares at June 30, 2023 and December 31, 2022			(4,585	)			(4,585	)
Additional paid-in capital			4,522,145				4,474,199
Accumulated other comprehensive income			21,612				12,528
Retained earnings			771,764				590,009
Total shareholders’ equity			5,310,959				5,072,174
Total liabilities and shareholders’ equity		$	9,298,741			$	9,114,616

 

7

 

Horizon Therapeutics plc

Condensed Consolidated Statements of Cash Flows (Unaudited)

(in thousands)

 

		Three Months Ended June 30,								Six Months Ended June 30,
		2023				2022				2023				2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income		$	127,071			$	60,974			$	181,755			$	265,235
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization expense			96,285				97,426				191,145				192,538
Equity-settled share-based compensation			60,271				45,149				118,391				92,449
Impairment of goodwill			—				56,171				—				56,171
Amortization of debt discount and deferred financing costs			1,308				2,327				2,779				3,904
Gain on sale of asset			(2,000	)			—				(2,000	)			—
Deferred income taxes			(4,642	)			30,864				(91,952	)			(3,032	)
Foreign exchange and other adjustments			(5,708	)			7,376				(6,143	)			10,566
Changes in operating assets and liabilities:
Accounts receivable			(92,670	)			11,152				(41,140	)			(40,513	)
Inventories			(5,833	)			22,818				(766	)			22,033
Prepaid expenses and other current assets			(60,191	)			(38,373	)			(108,816	)			(71,578	)
Accounts payable			7,807				(48,047	)			(70,233	)			(11,980	)
Accrued trade discounts and rebates			9,386				(27,047	)			(552	)			20,232
Accrued expenses and other current liabilities			20,532				36,874				63,390				(76,901	)
Other non-current assets and liabilities			9,851				(8,468	)			11,931				5,863
Net cash provided by operating activities			161,467				249,196				247,789				464,987
CASH FLOWS FROM INVESTING ACTIVITIES:
Payments for acquisitions, net of cash acquired			—				—				—				(3,122	)
Purchases of property, plant and equipment			(18,466	)			(10,154	)			(42,594	)			(24,352	)
Payments for long-term investments			(1,560	)			(6,443	)			(4,183	)			(4,847	)
Receipts from long-term investments			—				4,416				—				4,416
Payments related to license and collaboration agreements			—				—				(15,000	)			(25,000	)
Net cash used in investing activities			(20,026	)			(12,181	)			(61,777	)			(52,905	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of term loans			(4,000	)			(4,000	)			(8,000	)			(8,000	)
Proceeds from the issuance of ordinary shares in conjunction with ESPP program			14,912				13,884				14,912				13,884
Proceeds from the issuance of ordinary shares in connection with stock option exercises			2,628				12,951				6,049				22,022
Payment of employee withholding taxes relating to share-based awards			(4,506	)			(5,419	)			(92,055	)			(120,527	)
Net cash provided by (used in) financing activities			9,034				17,416				(79,094	)			(92,621	)
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash			2,539				(4,396	)			4,908				(6,317	)
Net increase in cash, cash equivalents and restricted cash			153,014				250,035				111,826				313,144
Cash, cash equivalents and restricted cash, beginning of the period(1)			2,316,400				1,647,265				2,357,588				1,584,156
Cash, cash equivalents and restricted cash, end of the period(1)		$	2,469,414			$	1,897,300			$	2,469,414			$	1,897,300

 

(1)	Amounts include restricted cash balance in accordance with ASU No. 2016-18. Cash and cash equivalents excluding restricted cash are shown on the balance sheet.

 

8

 

Horizon Therapeutics plc

GAAP to Non-GAAP Reconciliations

Net Income and Earnings Per Share (Unaudited)

(in thousands, except share and per share data)

 

		Three Months Ended June 30,								Six Months Ended June 30,
		2023				2022				2023				2022
GAAP net income		$	127,071			$	60,974			$	181,755			$	265,235
Non-GAAP adjustments:
Acquisition/divestiture-related costs			52				1,023				733				2,612
Transaction-related costs			16,539				—				26,323				—
(Gain) loss on equity security investments			(2,437	)			438				(2,789	)			5,084
Restructuring and realignment costs			854				1,253				2,676				1,790
Manufacturing facility start-up costs			1,896				1,582				5,372				2,389
Amortization and step-up:
Intangible amortization expense			89,598				91,335				178,212				180,595
Inventory step-up expense			1,572				17,362				31,315				44,563
Amortization of debt discount and deferred financing costs			1,308				2,327				2,779				3,904
Impairment of goodwill			—				56,171				—				56,171
Gain on sale of asset			(2,000	)			—				(2,000	)			—
Share-based compensation			60,271				45,149				118,391				92,449
Depreciation			6,687				6,091				12,933				11,943
Total of pre-tax non-GAAP adjustments			174,340				222,731				373,945				401,500
Income tax effect of pre-tax non-GAAP adjustments			(21,354	)			(29,919	)			(81,297	)			(97,131	)
Total of non-GAAP adjustments			152,986				192,812				292,648				304,369
Non-GAAP net income		$	280,057			$	253,786			$	474,403			$	569,604
Non-GAAP Earnings Per Share:
Weighted average ordinary shares - Basic			228,743,143				230,020,004				228,571,356				229,559,715
Non-GAAP Earnings Per Share - Basic:
GAAP earnings per share - Basic		$	0.56			$	0.27			$	0.80			$	1.16
Non-GAAP adjustments			0.66				0.83				1.28				1.32
Non-GAAP earnings per share - Basic		$	1.22			$	1.10			$	2.08			$	2.48
Weighted average ordinary shares - Diluted
Weighted average ordinary shares - Basic			228,743,143				230,020,004				228,571,356				229,559,715
Ordinary share equivalents			5,192,448				6,146,380				5,366,793				6,517,432
Weighted average ordinary shares - Diluted			233,935,591				236,166,384				233,938,149				236,077,147
Non-GAAP Earnings Per Share - Diluted
GAAP earnings per share - Diluted		$	0.54			$	0.26			$	0.78			$	1.12
Non-GAAP adjustments			0.66				0.81				1.25				1.29
Non-GAAP earnings per share - Diluted		$	1.20			$	1.07			$	2.03			$	2.41

 

9

 

Horizon Therapeutics plc

GAAP to Non-GAAP Reconciliations

EBITDA and Adjusted EBITDA (Unaudited)

(in thousands)

 

		Three Months Ended June 30,								Six Months Ended June 30,
		2023				2022				2023				2022
GAAP net income		$	127,071			$	60,974			$	181,755			$	265,235
Depreciation			6,687				6,091				12,933				11,943
Amortization and step-up:
Intangible amortization expense			89,598				91,335				178,212				180,595
Inventory step-up expense			1,572				17,362				31,315				44,563
Interest expense, net (including amortization of debt discount and deferred financing costs)			12,098				21,409				27,638				42,665
Expense (benefit) for income taxes			8,181				3,813				(27,301	)			(27,709	)
EBITDA		$	245,207			$	200,984			$	404,552			$	517,292
Other non-GAAP adjustments:
Share-based compensation			60,271				45,149				118,391				92,449
(Gain) loss on equity security investments			(2,437	)			438				(2,789	)			5,084
Impairment of goodwill			—				56,171				—				56,171
Gain on sale of asset			(2,000	)			—				(2,000	)			—
Acquisition/divestiture-related costs			52				1,023				733				2,612
Transaction-related costs			16,539				—				26,323				—
Manufacturing facility start-up costs			1,896				1,582				5,372				2,389
Restructuring and realignment costs			854				1,253				2,676				1,790
Total of other non-GAAP adjustments			75,175				105,616				148,706				160,495
Adjusted EBITDA		$	320,382			$	306,600			$	553,258			$	677,787

 

10

 

Horizon Therapeutics plc

GAAP to Non-GAAP Reconciliations

Operating Income (Unaudited)

(in thousands)

 

		Three Months Ended June 30,								Six Months Ended June 30,
		2023				2022				2023				2022
GAAP operating income		$	142,841			$	88,557			$	178,835			$	282,874
Non-GAAP adjustments:
Acquisition/divestiture-related costs			52				1,023				733				2,612
Transaction-related costs			16,539				—				26,323				—
Restructuring and realignment costs			854				1,253				2,676				1,790
Manufacturing facility start-up costs			1,896				1,582				5,372				2,389
Amortization and step-up:
Intangible amortization expense			89,598				91,335				178,212				180,595
Inventory step-up expense			1,572				17,362				31,315				44,563
Impairment of goodwill			—				56,171				—				56,171
Gain on sale of asset			(2,000	)			—				(2,000	)			—
Share-based compensation			60,271				45,149				118,391				92,449
Depreciation			6,687				6,091				12,933				11,943
Total of non-GAAP adjustments			175,469				219,966				373,955				392,512
Non-GAAP operating income		$	318,310			$	308,523			$	552,790			$	675,386
Foreign exchange gain			326				28				417				448
Other income (expense), net			1,746				(1,951	)			51				1,953
Adjusted EBITDA		$	320,382			$	306,600			$	553,258			$	677,787

 

11

 

Horizon Therapeutics plc

GAAP to Non-GAAP Reconciliations

Gross Profit and Operating Cash Flow (Unaudited)

(in thousands, except percentages)

 

		Three Months Ended June 30,								Six Months Ended June 30,
		2023				2022				2023				2022
Non-GAAP Gross Profit:
GAAP gross profit		$	725,001			$	646,195			$	1,348,497			$	1,316,378
Non-GAAP gross profit adjustments:
Acquisition/divestiture-related costs			52				(119	)			20				(1,423	)
Intangible amortization expense			89,259				90,439				177,537				179,164
Inventory step-up expense			1,572				17,362				31,315				44,563
Share-based compensation			3,141				2,294				5,803				4,471
Depreciation			130				55				178				111
Total of Non-GAAP adjustments			94,154				110,031				214,853				226,886
Non-GAAP gross profit		$	819,155			$	756,226			$	1,563,350			$	1,543,264
GAAP gross profit %			76.7	%			73.7	%			75.9	%			74.7	%
Non-GAAP gross profit %			86.7	%			86.3	%			88.0	%			87.6	%
GAAP cash provided by operating activities		$	161,467			$	249,196			$	247,789			$	464,987
Cash payments for acquisition/divestiture-related costs			11				748				51				5,196
Cash payments for restructuring and realignment costs			931				570				5,572				1,144
Cash payments for manufacturing facility start-up costs			2,116				895				5,910				2,663
Cash payments for transaction-related costs			14,074				—				20,668				—
Non-GAAP operating cash flow		$	178,599			$	251,409			$	279,990			$	473,990

 

12

 

Horizon Therapeutics plc

GAAP to Non-GAAP Tax Rate Reconciliation (Unaudited)

(in millions, except percentages and per share amounts)

 

		Q2 2023
		Pre-tax Net Income				Income Tax Expense				Tax Rate				Net Income				Diluted Earnings Per Share
As reported - GAAP		$	135.3			$	8.2				6.0	%		$	127.1			$	0.54
Non-GAAP adjustments			174.3				21.4								153.0
Non-GAAP		$	309.6			$	29.5				9.5	%		$	280.1			$	1.20

 

		Q2 2022
		Pre-tax Net Income				Income Tax Expense				Tax Rate				Net Income				Diluted Earnings Per Share
As reported - GAAP		$	64.8			$	3.8				5.9	%		$	61.0			$	0.26
Non-GAAP adjustments			222.7				29.9								192.8
Non-GAAP		$	287.5			$	33.7				11.7	%		$	253.8			$	1.07

 

		YTD 2023
		Pre-tax Net Income				Income Tax (Benefit) Expense				Tax Rate				Net Income				Diluted Earnings Per Share
As reported - GAAP		$	154.5			$	(27.3	)			(17.7	)%		$	181.8			$	0.78
Non-GAAP adjustments			373.9				81.3								292.6
Non-GAAP		$	528.4			$	54.0				10.2	%		$	474.4			$	2.03

 

		YTD 2022
		Pre-tax Net Income				Income Tax (Benefit) Expense				Tax Rate				Net Income				Diluted Earnings Per Share
As reported - GAAP		$	237.5			$	(27.7	)			(11.7	)%		$	265.2			$	1.12
Non-GAAP adjustments			401.5				97.1								304.4
Non-GAAP		$	639.0			$	69.4				10.9	%		$	569.6			$	2.41

 

13

 

Horizon Therapeutics plc

Certain Income Statement Line Items - Non-GAAP Adjusted

For the Three Months Ended June 30, 2023 (Unaudited)

(in thousands)

 

		Cost of Goods				Research &				Selling, General				Gain on sale				Interest				Other Income				Income Tax
		Sold				Development				& Administrative				of asset				Expense, net				(Expense), net				Expense
GAAP as reported		$	(219,958	)		$	(150,035	)		$	(434,125	)		$	2,000			$	(12,098	)		$	4,183			$	(8,181	)
Non-GAAP Adjustments:
Acquisition/divestiture-related costs(1)			52				—				—				—				—				—				—
Transaction-related costs(2)			—				—				16,539				—				—				—				—
Gain on equity security investments(3)			—				—				—				—				—				(2,437	)			—
Restructuring and realignment costs(4)			—				253				601				—				—				—				—
Manufacturing facility start-up costs(5)			—				—				1,896				—				—				—				—
Amortization and step-up:
Intangible amortization expense(6)			89,259				—				339				—				—				—				—
Inventory step-up expense(7)			1,572				—				—				—				—				—				—
Amortization of debt discount and deferred financing costs(8)			—				—				—				—				1,308				—				—
Gain on sale of asset(9)			—				—				—				(2,000	)			—				—				—
Share-based compensation(10)			3,141				9,395				47,735				—				—				—				—
Depreciation(11)			130				588				5,969				—				—				—				—
Income tax effect on pre-tax non-GAAP adjustments(12)			—				—				—				—				—				—				(21,354	)
Total of non-GAAP adjustments			94,154				10,236				73,079				(2,000	)			1,308				(2,437	)			(21,354	)
Non-GAAP		$	(125,804	)		$	(139,799	)		$	(361,046	)		$	—			$	(10,790	)		$	1,746			$	(29,535	)

Horizon Therapeutics plc

Certain Income Statement Line Items - Non-GAAP Adjusted

For the Three Months Ended June 30, 2022 (Unaudited)

(in thousands)

 

		Cost of Goods				Research &				Selling, General				Impairment of				Interest				Other (Expense)				Income Tax
		Sold				Development				& Administrative				goodwill				Expense, net				Income, net				Expense
GAAP as reported		$	(230,216	)		$	(103,246	)		$	(398,221	)		$	(56,171	)		$	(21,409	)		$	(2,389	)		$	(3,813	)
Non-GAAP Adjustments:
Acquisition/divestiture-related costs(1)			(119	)			—				1,142				—				—				—				—
Loss on equity security investments(3)			—				—				—				—				—				438				—
Restructuring and realignment costs(4)			—				804				449				—				—				—				—
Manufacturing facility start-up costs(5)			—				—				1,582				—				—				—				—
Amortization and step-up:
Intangible amortization expense(6)			90,439				—				896				—				—				—				—
Inventory step-up expense(7)			17,362				—				—				—				—				—				—
Amortization of debt discount and deferred financing costs(8)			—				—				—				—				2,327				—				—
Share-based compensation(10)			2,294				6,742				36,113				—				—				—				—
Depreciation(11)			55				267				5,769				—				—				—				—
Impairment of goodwill(13)			—				—				—				56,171				—				—				—
Income tax effect on pre-tax non-GAAP adjustments(12)			—				—				—				—				—				—				(29,919	)
Total of non-GAAP adjustments			110,031				7,813				45,951				56,171				2,327				438				(29,919	)
Non-GAAP		$	(120,185	)		$	(95,433	)		$	(352,270	)		$	—			$	(19,082	)		$	(1,951	)		$	(33,732	)

 

14